Orion Oyj (OTCMKTS:ORINY) Sees Significant Drop in Short Interest

Orion Oyj (OTCMKTS:ORINY) was the recipient of a significant decline in short interest in the month of March. As of March 15th, there was short interest totalling 300 shares, a decline of 50.0% from the February 28th total of 600 shares. Approximately 0.0% of the company’s shares are sold short. Based on an average daily trading volume, of 1,400 shares, the short-interest ratio is currently 0.2 days.

Orion Oyj Trading Up 2.4 %

ORINY traded up $0.68 during midday trading on Friday, reaching $29.35. 680 shares of the company’s stock traded hands, compared to its average volume of 3,220. Orion Oyj has a 52 week low of $17.50 and a 52 week high of $30.57. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.42 and a quick ratio of 1.41. The firm has a fifty day moving average of $27.98 and a two-hundred day moving average of $25.68. The stock has a market capitalization of $8.28 billion, a price-to-earnings ratio of 23.29 and a beta of 0.25.

Orion Oyj (OTCMKTS:ORINY) last announced its earnings results on Tuesday, February 25th. The company reported $0.28 EPS for the quarter. The company had revenue of $463.41 million during the quarter. Orion Oyj had a return on equity of 39.49% and a net margin of 23.01%. On average, equities analysts anticipate that Orion Oyj will post 1.18 earnings per share for the current fiscal year.

Orion Oyj Increases Dividend

The company also recently disclosed a dividend, which will be paid on Tuesday, April 29th. Shareholders of record on Monday, April 7th will be given a dividend of $0.4478 per share. This is a boost from Orion Oyj’s previous dividend of $0.24. The ex-dividend date of this dividend is Monday, April 7th. Orion Oyj’s payout ratio is presently 24.00%.

Analyst Ratings Changes

Separately, Nordea Equity Research cut Orion Oyj to a “hold” rating in a report on Tuesday, February 4th.

About Orion Oyj

Orion Oyj develops, manufactures, and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients (APIs) in Finland, Scandinavia, rest of Europe, North America, and internationally. The company provides prescription drugs and self-care products, which includes Nubeqa for the treatment of prostate cancer; Precedex, Dexdor, and Precedex for human use; Burana for inflammatory pain; Divina series for menopausal symptoms; Trexan for rheumatoid arthritis and cancer; Stalevo, Entacapone, and Comtess/Comtan for Parkinson’s disease; Biosimilars for rheumatoid arthritis and inflammatory bowel diseases; and Simdax for acute decompensated heart failure, as well as Fareston for breast cancer.